Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults

Srilatha Edupuganti, Stephen C. De Rosa, Marnie Elizaga, Yiwen Lu, Xue Han, Yunda Huang, Edith Swann, Laura Polakowski, Spyros A. Kalams, Michael C. Keefer, Janine Maenza, Megan C. Wise, Jian Yan, Matthew P. Morrow, Amir Sada Khan, Jean Boyer, Laurent Humeau, S. M. White, Niranjan Y. Sardesai, Mark L. Bagarazzi, Peter B. Gilbert, James G. Kublin, Lawrence Corey, David B. Weiner, on behalf of the Hvtn 098 Study Team, the NIAID-Funded Hiv Vaccine Trials NetworkVaccines 2020 · DOI

TL;DR

This study investigated the safety, tolerability, and acceptability of a novel HIV-1 DNA vaccine (PENNVAX-GP) delivered via intramuscular (IM) or intradermal (ID) electroporation (EP), with or without an IL-12 adjuvant. Both delivery methods proved safe and well-tolerated, with ID/EP showing promise as a dose-sparing approach with comparable immune responses to IM/EP, despite more frequent, transient skin lesions.

What Problem Does This Paper Address?

Developing an effective HIV-1 vaccine remains a significant global health challenge. DNA vaccines offer advantages in terms of ease of design, production, and safety compared to other vaccine platforms. However, previous HIV-1 DNA vaccines have struggled to elicit sufficiently robust immune responses in humans to advance into efficacy trials. Researchers are exploring various strategies to enhance DNA vaccine immunogenicity, including improved delivery methods like electroporation (EP) and the use of cytokine adjuvants such as IL-12. Electroporation uses brief electrical pulses to create temporary pores in cell membranes, facilitating the entry of DNA into cells. While IM EP has shown promise, intradermal (ID) EP is being investigated as a potentially more effective route due to the higher concentration of antigen-presenting cells in the skin. This study specifically addresses the need to evaluate the safety and tolerability of a new HIV-1 DNA vaccine candidate (PENNVAX-GP) delivered via both IM and ID EP, with and without the IL-12 adjuvant, in healthy adults.

Methods

The HVTN 098 trial was a Phase 1 study that enrolled 94 healthy, HIV-uninfected adults. Participants were randomized into four groups: three receiving the PENNVAX-GP DNA vaccine with or without IL-12 via intradermal electroporation (ID/EP) at varying doses, and one group receiving the vaccine via intramuscular electroporation (IM/EP) with IL-12. A control group received placebo via either ID/EP or IM/EP. Vaccinations were administered at months 0, 1, 3, and 6.

Key methods for assessing safety and tolerability included:

  • Solicited Local and Systemic Reactogenicity: Participants reported on symptoms like pain, tenderness, erythema, induration, malaise, fatigue, myalgia, and headache for seven days post-vaccination.
  • Visual Analog Scale (VAS) for Pain: Pain intensity at the injection site was measured immediately after vaccination and at subsequent time points.
  • Injection Site Lesion Assessment: Skin changes such as scabs, eschars, scars, and pigmentation changes were documented and monitored.
  • Adverse Event (AE) Reporting: All AEs were recorded for 12 months post-vaccination, with serious AEs (SAEs) monitored for longer.
  • Acceptability Questionnaires: Participants completed surveys at multiple time points to assess their comfort level with EP, the appearance of injection sites, and their willingness to recommend EP vaccination.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • ID/EP as a Promising Alternative: The study highlights ID/EP as a safe and tolerable route for HIV-1 DNA vaccine delivery, comparable to IM/EP in terms of safety and immune response, while potentially allowing for dose-sparing.
  • Transient Skin Lesions with ID/EP: While ID/EP was associated with more frequent and noticeable skin lesions (scabs, eschars, pigmentation changes) compared to IM/EP, these were generally transient and resolved within six months, and did not lead to study discontinuation.
  • Pain is Manageable: Electroporation, while causing acute pain, was generally well-tolerated, with discomfort subsiding quickly. ID/EP was consistently less painful than IM/EP.
  • Acceptability is High, Especially for Serious Diseases: Participants found the EP experience acceptable, and a high percentage indicated willingness to recommend EP for an effective HIV vaccine, particularly if the disease is serious.
  • IL-12 Adjuvant Safety: The co-administration of the IL-12 adjuvant via ID/EP was found to be safe and well-tolerated.

Key Results

  • Safety: Both ID/EP and IM/EP vaccination regimens were safe and well-tolerated in healthy adults, with no serious safety events related to the vaccines or administration method.
  • Pain: VAS pain scores were significantly lower immediately after vaccination in the ID/EP groups (median 4.1–4.6) compared to the IM/EP group (median 6–6.5) (p < 0.01).
  • Reactogenicity: Local injection site reactogenicity, particularly pain and tenderness, was greater in the IM/EP group. Systemic reactogenicity was generally mild to moderate and not significantly different across groups.
  • Skin Lesions: 100% of ID/EP participants had visible injection site lesions at two weeks post-vaccination, with scab/eschar being common. These lesions faded over time, with 49% still present at six months. IM/EP participants had minimal skin lesions.
  • Acceptability: 82% of IM/EP and 92% of ID/EP participants reported similar levels of anxiety and acceptable discomfort. 99% of ID/EP and 93% of IM/EP participants would recommend EP for an effective HIV vaccine if it felt the same as their trial experience.

Limitations and Future Work

  • No IM/EP without IL-12 Group: The study did not include a direct comparison of IM/EP without the IL-12 adjuvant, relying on previous studies for comparison.
  • Skin Lesion Persistence: While generally acceptable, the persistence of skin lesions in some ID/EP participants for up to six months warrants further consideration.
  • Future Exploration: The authors suggest further exploration of EP delivery of DNA vaccines for emerging infectious diseases like COVID-19 and their acceptability among the general population. They also point to the immunogenicity findings (higher antibody responses with ID/IL-12 vs. IM/IL-12) as a key area for future research.

Summary updated

Abstract

ID/EP and IM/EP are distinct experiences; however, HIV-1 DNA vaccination by either route was safe, tolerable and acceptable by most study participants.
BibTeX
@inproceedings{edupuganti2020intramuscular,
  author = {Srilatha Edupuganti and Stephen C. De Rosa and Marnie Elizaga and Yiwen Lu and Xue Han and Yunda Huang and Edith Swann and Laura Polakowski and Spyros A. Kalams and Michael C. Keefer and Janine Maenza and Megan C. Wise and Jian Yan and Matthew P. Morrow and Amir Sada Khan and Jean Boyer and Laurent Humeau and S. M. White and Niranjan Y. Sardesai and Mark L. Bagarazzi and Peter B. Gilbert and James G. Kublin and Lawrence Corey and David B. Weiner and on behalf of the HVTN 098 Study Team and the NIAID-Funded HIV Vaccine Trials Network},
  title = {{Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults}},
  booktitle = {Vaccines},
  year = {2020},
  doi = {10.3390/vaccines8040741},
}
Figure